Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have the following:
• • Stage III or IV HIV infection.
• • Provide informed consent.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• • Kaposi's sarcoma lesions in the proposed treatment sites.
• • Liable to require radiation or chemotherapy during the course of the study.
• • Not likely to survive the length of the study.
• * Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:
• • holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.
• Concurrent Medication:
• Excluded:
• • Other Immunomodulators.
• Concurrent Treatment:
• Excluded:
• • Radiation.
• Patients with the following are excluded:
• • Kaposi's sarcoma lesions in the proposed treatment sites.
• • Liable to require radiation or chemotherapy during the course of the study.
• • Not likely to survive the length of the study.
• • Obvious ultra-violet-irradiated skin damage in the treatment areas.
• • Allergy to lidocaine.
• Prior Medication:
• Excluded:
• • Prior DNCB therapy.